台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

#0167 Association of insulin resistance indices with kidney stones and their recurrence in a non-diabetic population: an analysis based on NHANES data from 2007-2018

04-24 • 觀看: 32 • 回應: 0 • doc
#1173 Comparison of Effect of Pterostilbene on Apoptosis of Bladder Cancer Cells at Different Stages

04-24 • 觀看: 33 • 回應: 0 • doc
#1143 Analysis of Neoadjuvant Chemoimmunotherapy in Muscle-Invasive Bladder Cancer

04-24 • 觀看: 35 • 回應: 0 • doc
#1127 Urothelial Cancer Screening in Lynch Syndrome: Addressing a Critical Gap in Early Detection

04-24 • 觀看: 33 • 回應: 0 • doc
#1123 Real world treatment outcomes for metastatic urothelial carcinoma

04-24 • 觀看: 33 • 回應: 0 • doc
#1118 Optimizing Perioperative Chemotherapy in Upper Tract Urothelial Carcinoma: A Real-World TriNetx Analysis of Neoadjuvant vs. Adjuvant Approaches

04-24 • 觀看: 39 • 回應: 0 • doc
#1073 Optimizing Urothelial Carcinoma Surveillance in Patients with Lynch Syndrome: A Role for Annual Cxbladder Testing?

04-24 • 觀看: 26 • 回應: 0 • doc
#0920 Increased Splenic Volume With Low Lymphocyte Percentage Predict Poor Oncologic Outcomes in Upper Tract Urothelial Carcinoma

04-24 • 觀看: 33 • 回應: 0 • doc
#0872 Intra-diverticular bladder urothelial carcinoma: Two rare cases and literature review

04-24 • 觀看: 38 • 回應: 0 • doc
#0774 OIP5-AS1 modulates cell proliferation, migration and invasion through ADAM9 via targeting miR-30c-5p in upper tract urothelial carcinoma

04-24 • 觀看: 29 • 回應: 0 • doc
#0741 Comparing low-dose and full-dose intravesical Sii-Onco BCG in patients with intermediate and high risk NMIBC: A prospective randomised study

04-24 • 觀看: 37 • 回應: 0 • doc
#0652 Real world study of enfortumab vedotin (EV) combine pembrolizumab treatment in locally advance or metastasis urothelial carcinoma

04-24 • 觀看: 36 • 回應: 0 • doc

Prev
43
44
45
46
47
48
49
50
51
52
Next
/ 1264